Vaginal Isonicotinic Acid Hydrazide Administration Prior to Insertion Levonorgestrel-releasing Intrauterine System

• Status: Recruiting
• Trial end date: 2021-05-30
• Target enrollment: 0
• Participant gender: Female

Summary

To investigate whether vaginal isonicotinic acid hydrazide (INH) administered before the levonorgestrel-releasing intrauterine system(IUs) insertion reduces failed insertions, insertion-related complications, and pain in Women With no Previous Vaginal Delivery.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Aswan University Hospital

Criteria

Inclusion Criteria:

• Non-pregnant women

• Women that did not receive any analgesics or Dinoprostone in the 24 hours prior to insertion

• Women who delivered only by cesarean section

Exclusion Criteria:

• Women with any uterine abnormalities as congenital anomalies, endometrial lesions, adenomyosis, fibroids.

• Those with a Category 3 or 4 conditions for intrauterine device insertion according to the WHO Medical Eligibility Criteria for contraceptive use

• Allergy to isonicotinic acid hydrazide

• Women refuse to participate in the study